Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing novel treatments for mood disorders: accelerating discovery.

Carol A Tamminga1, Charles B Nemeroff, Randy D Blakely

  • 1Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, Maryland 21228, USA.

Biological Psychiatry
|October 4, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-Dose Buprenorphine Following Ketamine Treatment for Suicidal Ideation in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.

The American journal of psychiatry·2026
Same author

General Anesthesia and Discrete Components of Ketamine Neurophysiology.

JAMA psychiatry·2026
Same author

Continuing Questions About Esketamine 5 Years After Approval: Response to Ahmed et al.

The American journal of psychiatry·2026
Same author

Comment on Buse et al. Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes. Diabetes Care 2025;48:2012-2020.

Diabetes care·2026
Same author

Stanford neuromodulation therapy for treatment-resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy.

World psychiatry : official journal of the World Psychiatric Association (WPA)·2026
Same author

Bifunctional Modulation of NMDA and Opioid Receptors in Ketamine Reinforcement and Misuse: Implications for Substance Use Disorder Treatment.

Biological psychiatry·2025

Advancing treatments for mood disorders requires integrating new research in pharmacogenetics and somatic therapies. This review explores opportunities to accelerate the discovery of novel mood disorder therapeutics.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Current pharmacologic treatments for mood disorders are summarized.
  • New directions and research initiatives are highlighted.

Purpose of the Study:

  • To review novel pharmacologic and somatic treatments for mood disorders.
  • To identify opportunities for accelerating therapeutic discovery.

Main Methods:

  • Literature review and synthesis of current research.
  • Discussion of basic and clinical research initiatives.
  • Exploration of human imaging, somatic therapeutics, and pharmacogenetics.

Main Results:

  • Advances in basic neuroscience, clinical testing, and industry interest present opportunities.

Related Experiment Videos

  • Pharmacogenetics offers a vast new area for research.
  • Consumer advocacy groups play an active role.

    • Conclusions:

    • Integrating scientific, clinical, and advocacy efforts is crucial.
    • Accelerating the discovery of mood disorder therapeutics requires a collaborative approach.
    • Novel approaches hold promise for improving mood disorder treatment.